Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Articles|May 21, 2023
POLL: What Did You Take Away From SCALE 2023?
Author(s)Dermatology Times Staff
Let us know what you learned from the 2023 SCALE meeting in Nashville, Tennessee.
Advertisement
As the 18th annual SCALE meeting ends today, attendees are able to walk away with practical content from 5 days of engaging sessions and live demonstrations. Whether you are a student, esthetician, physician assistant, or dermatologist, SCALE 2023 welcomed everyone to learn from world-class faculty.
What did you take away from SCALE 2023?
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
4
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
5